CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021

Rhea-AI Summary

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) will host a conference call on March 25, 2021, at 4:30 PM ET to discuss its Q4 and full-year 2020 financial results, along with a business update. The company is focused on developing therapies for chronic liver diseases, particularly its candidate seladelpar for primary biliary cholangitis (PBC), which has received various designations from the FDA and EMA. CymaBay is commencing a global Phase 3 study for seladelpar, aiming to evaluate its safety and efficacy in treating PBC patients.

Positive

• Commencing a global Phase 3 study for seladelpar targeting PBC.
• Seladelpar has received orphan drug designation and breakthrough therapy status from regulatory bodies.

Negative

• None.

NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 25, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2020 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13715944. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC. For more information about RESPONSE, please visit: www.pbcstudies.com.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

What are the details of CymaBay's upcoming conference call?

CymaBay will host a conference call on March 25, 2021, at 4:30 PM ET to discuss its Q4 and full-year 2020 financial results and provide a business update.

What is the focus of CymaBay Therapeutics?

CymaBay Therapeutics focuses on developing therapies for liver diseases, specifically targeting unmet medical needs.

What is seladelpar and its significance for CymaBay?

Seladelpar is CymaBay's lead product candidate, a PPARδ agonist for treating primary biliary cholangitis (PBC), which has received significant regulatory designations.

What kind of study is CymaBay commencing for seladelpar?

CymaBay is starting a global, 52-week, placebo-controlled Phase 3 study called RESPONSE to evaluate the safety and efficacy of seladelpar in patients with PBC.